Charles Schwab’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$101M Buy
1,157,580
+37,621
+3% +$2.27M 0.01% 793
2026
Q1
$45.1M Buy
1,119,959
+57,858
+5% +$2.16M 0.01% 1234
2025
Q4
$37M Sell
1,062,101
-8,180
-0.8% -$643K 0.01% 1351
2025
Q3
$89M Buy
1,070,281
+255,826
+31% +$18.5M 0.01% 785
2025
Q2
$59.8M Sell
814,455
-217,269
-21% -$15.8M 0.01% 988
2025
Q1
$118M Sell
1,031,724
-19,836
-2% -$1.21M 0.02% 577
2024
Q4
$53M Buy
1,051,560
+25,073
+2% +$1.31M 0.01% 1091
2024
Q3
$47.5M Buy
1,026,487
+53,191
+5% +$1.89M 0.01% 1157
2024
Q2
$31.6M Buy
973,296
+39,835
+4% +$1.09M 0.01% 1374
2024
Q1
$23.5M Buy
933,461
+33,017
+4% +$780K 0.01% 1518
2023
Q4
$29.2M Buy
900,444
+39,111
+5% +$1.07M 0.01% 1354
2023
Q3
$23.5M Buy
861,333
+17,636
+2% +$510K 0.01% 1402
2023
Q2
$18.8M Sell
843,697
-46,266
-5% -$1.06M 0.01% 1546
2023
Q1
$19.3M Sell
889,963
-113
-0% -$2.48K 0.01% 1503
2022
Q4
$18.1M Buy
890,076
+67,419
+8% +$1.69M 0.01% 1512
2022
Q3
$21.1M Buy
822,657
+7,465
+0.9% +$200K 0.01% 1339
2022
Q2
$19.4M Buy
815,192
+29,476
+4% +$642K 0.01% 1433
2022
Q1
$17.7M Buy
785,716
+105,951
+16% +$2.25M 0.01% 1643
2021
Q4
$13.5M Sell
679,765
-85,672
-11% -$1.74M ﹤0.01% 1844
2021
Q3
$15.1M Sell
765,437
-105
-0% -$2.2K ﹤0.01% 1784
2021
Q2
$16.8M Sell
765,542
-24,867
-3% -$553K 0.01% 1707
2021
Q1
$18.8M Buy
790,409
+26,454
+3% +$706K 0.01% 1577
2020
Q4
$20M Buy
763,955
+14,173
+2% +$299K 0.01% 1411
2020
Q3
$13.1M Sell
749,782
-16,076
-2% -$256K 0.01% 1500
2020
Q2
$12.9M Buy
765,858
+74,478
+11% +$1.05M 0.01% 1475
2020
Q1
$8.22M Buy
691,380
+4,408
+0.6% +$54.5K ﹤0.01% 1570
2019
Q4
$8.31M Buy
686,972
+86,617
+14% +$1.21M ﹤0.01% 1747
2019
Q3
$8.49M Buy
600,355
+8,056
+1% +$99K 0.01% 1698
2019
Q2
$6.61M Buy
592,299
+10,780
+2% +$120K ﹤0.01% 1837
2019
Q1
$6.83M Buy
581,519
+19,250
+3% +$239K ﹤0.01% 1822
2018
Q4
$7.51M Buy
562,269
+56
+0% +$740 0.01% 1652
2018
Q3
$7.88M Buy
562,213
+60,276
+12% +$842K 0.01% 1790
2018
Q2
$7.89M Buy
501,937
+11,274
+2% +$196K 0.01% 1750
2018
Q1
$8.07M Buy
490,663
+9,739
+2% +$180K 0.01% 1649
2017
Q4
$8.69M Buy
480,924
+66,749
+16% +$1.21M 0.01% 1579
2017
Q3
$7.99M Buy
414,175
+43,602
+12% +$650K 0.01% 1601
2017
Q2
$4.37M Buy
370,573
+30,591
+9% +$333K ﹤0.01% 1887
2017
Q1
$3.73M Buy
339,982
+19,527
+6% +$172K ﹤0.01% 1925
2016
Q4
$2.33M Buy
320,455
+41,054
+15% +$322K ﹤0.01% 2124
2016
Q3
$1.82M Buy
279,401
+162,495
+139% +$945K ﹤0.01% 2181
2016
Q2
$639K Buy
116,906
+30,400
+35% +$158K ﹤0.01% 2506
2016
Q1
$405K Hold
86,506
﹤0.01% 2662
2015
Q4
$431K Hold
86,506
﹤0.01% 2715
2015
Q3
$326K Hold
86,506
﹤0.01% 2793
2015
Q2
$520K Buy
86,506
+18,106
+26% +$111K ﹤0.01% 2662
2015
Q1
$384K Hold
68,400
﹤0.01% 2737
2014
Q4
$206K Hold
68,400
﹤0.01% 2973
2014
Q3
$184K Hold
68,400
﹤0.01% 2971
2014
Q2
$192K Hold
68,400
﹤0.01% 3005
2014
Q1
$299K Hold
68,400
﹤0.01% 2804
2013
Q4
$221K Hold
68,400
﹤0.01% 2930
2013
Q3
$111K Hold
68,400
﹤0.01% 3024
2013
Q2
$122K Buy
+68,400
New +$123K ﹤0.01% 3007

Other funds holding CORT

Charles Schwab's CORT Position: Q2 2026 in Review

Charles Schwab increased its Corcept Therapeutics (CORT) stake by 3.4% in Q2 2026, buying an estimated $2.27M and bringing the position to 1,157,580 shares worth $101M. The position accounts for 0.01% of the portfolio, ranked #793.

Charles Schwab first reported a position in CORT in Q2 2013 and has held it in 53 quarters since. The position peaked at $118M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Charles Schwab held 1,157,580 shares of Corcept Therapeutics worth $101M as of Q2 2026.
  • Charles Schwab bought 37,621 Corcept Therapeutics shares in Q2 2026, an estimated $2.27M.
  • Corcept Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #793 holding.
  • Charles Schwab first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Corcept Therapeutics position peaked at $118M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.